A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

Peer Review reports

Original Submission
25 Apr 2012	Submitted	Original manuscript
16 Aug 2012	Reviewed	Reviewer Report - Felice Iasevoli
20 Aug 2012	Reviewed	Reviewer Report - Jason Uslaner
24 Aug 2012	Reviewed	Reviewer Report - Wen-Jun Gao
30 Aug 2012	Reviewed	Reviewer Report - Bita Moghaddam
17 Jan 2013	Author responded	Author comments - Sara Kollack-Walker
Resubmission - Version 2
17 Jan 2013	Submitted	Manuscript version 2
9 Feb 2013	Reviewed	Reviewer Report - Felice Iasevoli
12 Feb 2013	Reviewed	Reviewer Report - Jason Uslaner
8 May 2013	Author responded	Author comments - Sara Kollack-Walker
Resubmission - Version 3
8 May 2013	Submitted	Manuscript version 3
Publishing
15 May 2013	Editorially accepted
22 May 2013	Article published	10.1186/1471-244X-13-143

Back to article page